Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

(2012) M. L. Huber et al.   JNCI-Journal of the National Cancer Institute

Pharmacotherapeutic Management of Locally Advanced Prostate Cancer

(2011) Jarad M. Martin et al.   DRUGS

Management of Side Effects of Androgen Deprivation Therapy

(2011) Mathis Grossmann et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer

(2010) Sumanta Kumar Pal et al.   MATURITAS

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosuppressive CD14+HLA-DRlow/−monocytes in prostate cancer

(2009) Stanimir Vuk-Pavlović et al.   PROSTATE

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE